**IRUXOL Mono Ointment**
Clostridiopeptidase A (collagenase and associated proteases)
Abbreviated Prescribing Information
Please refer to Summary of Product Characteristics (SmPC) before prescribing

**Presentation:** Tubes containing 10g or 20g brown lipophilic ointment. Each gram of ointment contains not less than 1.2 units of clostridiopeptidase A and not less than 0.24 units of associated proteases.

**Indications:** Enzymatic debridement of necrotising wounds, including leg and decubital ulcers.

**Dosage and Administration:** For topical administration. Apply a layer of approx. 2mm of ointment to the dressing or directly to the slightly moistened area to be treated once daily. Close contact to the wound surface should be assured. Change the dressing once daily. Occasionally, twice daily use may be required (may possibly increase activity). Sufficient moisture must be present in the wound area during therapy. In dry wounds, moisten the wound base with 0.9% NaCl or other solutions which are well tolerated by the tissue. Soften dry and hard crusts first by applying a moist dressing. Discontinue treatment when the whole surface of the wound is clean. If infection is present, consider an appropriate antibiotic treatment. Protect the wound edges and healthy skin to avoid irritation.

**Contraindications, Precautions and Warnings:** Contra-indicated in patients hypersensitive to any of the ingredients. Avoid contact with eyes and mucosa. In diabetic patients, moisten dry gangrenes with caution to avoid conversion to moist gangrene. If reduction in necrotic tissue is not observed within 14 days of commencing treatment, discontinue and replace with an alternative method of debridement.

**Interactions:** Do not use in the presence of antiseptics, heavy metals, detergents and soaps. Tyrothricin, gramicidin and tetracyclines should not be used locally with IRUXOL Mono.

**Pregnancy and lactation:** Only administer during the first three months of pregnancy when strictly indicated. Excretion into breast milk is unlikely.

**Undesirable Effects:** Local pain, pruritus, burning, erythema. Consult SmPC for further information about adverse events.

**Legal Category:** POM

**Product Authorisation No. :** PA 518/7/1

**Marketing Authorisation Holder:** T.J. Smith & Nephew Ltd., Hessle Road Hull, HU3 2BN, UK

Further information is available on request from the Marketing Authorisation Holder

**Date of Preparation:** August 2012

**Asset Number:** 38263

Adverse events should be reported to:
Smith & Nephew Healthcare Ltd.,
101 Hessle Road, Hull HU3 2BN, UK
Tel : 1890 224 226 E-mail: advice@smith-nephew.com